Evidence map›Paper›PMID 35362470›Full record

ArticleActa crystallographica. Section D, Structural biology2022

Molecular insight into 2-phosphoglycolate activation of the phosphatase activity of bisphosphoglycerate mutase.

Anfal S Aljahdali, Faik N Musayev, John W Burgner, Mohini S Ghatge, Vibha Shekar, Yan Zhang, Abdelsattar M Omar, Martin K Safo

Open access · hybridAbstract read
In one paragraph

Article in Acta crystallographica. Section D, Structural biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Anfal S AljahdaliDepartment of Pharmaceutical Chemistry, King Abdulaziz University, Alsulaymanyah, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-6192-5213
Faik N MusayevDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, 800 East Leigh Street, Richmond, VA 23298, USA.
John W BurgnerDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, 800 East Leigh Street, Richmond, VA 23298, USA.
Mohini S GhatgeDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, 800 East Leigh Street, Richmond, VA 23298, USA.
Vibha ShekarThe Institute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, 800 East Leigh Street, Richmond, VA 23298, USA.
Yan ZhangDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, 800 East Leigh Street, Richmond, VA 23298, USA.
Abdelsattar M OmarDepartment of Pharmaceutical Chemistry, King Abdulaziz University, Alsulaymanyah, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-9825-3465
Martin K SafoDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, 800 East Leigh Street, Richmond, VA 23298, USA.
Virginia Commonwealth University · USKing Abdulaziz University · SA

Funding

Hemoglobin Modifiers for Sickle Cell Disease TherapyR01MD009124 · NIMHD · VIRGINIA COMMONWEALTH UNIVERSITY · PI SAFO, MARTIN K · 2014 to 2018
$2.1M
Targeted Identification of Dual Acting Antisickling Agents for Sickle Cell Disease TherapyR61HL156158 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI ABDULMALIK, OSHEIZA Y, SAFO, MARTIN K · 2021 to 2022
$1.1M
X-ray Crystallographic Data Collection SystemS10OD021756 · OD · VIRGINIA COMMONWEALTH UNIVERSITY · PI SAFO, MARTIN K · 2017 to 2017
$600k
Targeted Identification of Dual Acting Antisickling Agents for Sickle Cell Disease TherapyR33HL156158 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI ABDULMALIK, OSHEIZA Y, SAFO, MARTIN K · 2023 to 2023
$572k
NHLBI NIH HHS R33 HL156158NHLBI NIH HHS R61 HL156158NIH HHS S10 OD021756NIH HHS S10OD021756 (MKS)NIMHD NIH HHS R01 MD009124NIMHD NIH HHS R01MD009124 (MKS)
6 · The paper itself

Abstract

Bisphosphoglycerate mutase (BPGM) is an erythrocyte-specific multifunctional enzyme that is responsible for the regulation of 2,3-bisphosphoglycerate (2,3-BPG) in red blood cells through its synthase and phosphatase activities; the latter enzymatic function is stimulated by the endogenous activator 2-phosphoglycolate (2-PG). 2,3-BPG is a natural allosteric effector of hemoglobin (Hb) that is responsible for decreasing the affinity of Hb for oxygen to facilitate tissue oxygenation. Here, crystal structures of BPGM with 2-PG in the presence and absence of 3-phosphoglycerate are reported at 2.25 and 2.48 Å resolution, respectively. Structure analysis revealed a new binding site for 2-PG at the dimer interface for the first time, in addition to the expected active-site binding. Also, conformational non-equivalence of the two active sites was observed as one of the sites was found in an open conformation, with the residues at the active-site entrance, including Arg100, Arg116 and Arg117, and the C-terminus disordered. The kinetic result is consistent with the binding of 2-PG to an allosteric or noncatalytic site as well as the active site. This study paves the way for the rational targeting of BPGM for therapeutic purposes, especially for the treatment of sickle cell disease.

Indexed as

Bisphosphoglycerate MutaseGlycolatesBinding SitesPhosphoric Monoester HydrolasesBisphosphoglycerate MutaseGlycolatesphosphoglycolatePhosphoric Monoester Hydrolases2,3-bisphosphoglycerate2-phosphoglycolatebisphosphoglycerate mutasekineticsphosphatasessynthasesX-ray crystallography

Identifiers

PMID35362470
PMCPMC8972806
OpenAlexW4220949217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.